CEPI | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights
CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership established in 2017 to accelerate the development...
CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership established in 2017 to accelerate the development of vaccines against future epidemics. It focuses on developing vaccines for various pathogens, including Ebola, Lassa virus, and COVID-19, and aims to compress vaccine development timelines to 100 days. CEPI also invests in platform technologies for rapid vaccine development and ensures fair allocation of vaccines worldwide through initiatives like COVAX.
Website
Size
51-200 employees
Industry
Research Services
Specialities
Epidemic Preparedness, Vaccine Development, Vaccine, Health, Science
🛍️ CEPI Product and Pricing News →
👔 CEPI CEO, Management and Leadership Team →
⚔️ CEPI Alternatives and Competitors →
💼 CEPI Hiring and Layoffs →
🤖 CEPI Developer, Integration and Automation News →
📈 CEPI Financials, Fundraising and Valuation News →
🛍️ CEPI Product and Pricing News
- In 2024, CEPI expanded its manufacturing network to India and Brazil and initiated Phase 2 clinical trials for a Lassa fever vaccine.
- CEPI is establishing vaccine safety benchmarking in Africa specifically for African vaccines.
- CEPI will support the inaugural meeting of the Lassa Coalition Governing Entity on January 16, 2024, to address Lassa fever in West Africa.
- Emma Wheatley, Executive Director Access & Business Development at CEPI, participated in a panel moderated by Dr. Steve Brozak on January 15, 2025.
- CEPI is developing a button that could enable vaccines to be mailed and self-administered like a sticker to address clinician shortages and needle phobia.
- CEPI's recent manuscript on Mpox outbreak response was published in Nature Medicine, detailing their preparedness strategies and assay development.
- CEPI is supporting new research with the University of Oxford and scientists in Kenya and Tanzania to assess Chikungunya disease burden in East Africa.
- CEPI included the mAB 1F5, now called MBP1F5, developed by Dr. Christopher Broder's lab, in its list of top innovations for 2024.
👔 CEPI CEO, Management and Leadership Team
⚔️ CEPI Alternatives and Competitors
- Gavi, the Vaccine Alliance |
- The Global Fund |
- International Vaccine Institute (IVI) |
- Bill & Melinda Gates Foundation |
- PATH |
- World Health Organization |
- IAVI
💼 CEPI Hiring and Layoffs
- CEPI is seeking an Executive Director of People & Organisation to lead HR initiatives and support its mission to reduce epidemic risks.
- Dr. Sall has joined CEPI in a new role, as announced by the Global Virus Network on December 10.
- Dr Sall will lead CEPI's manufacturing and supply chain strategy to improve global epidemic and pandemic preparedness by increasing manufacturing capacity in underserved regions.
- Sarah Roberts has left CEPI as the Head of R&D Events & Admin in the United Kingdom to join CityZen Property Management LTD as the Client Accounts & Contract Compliance Manager.
- Dr. Amadou Alpha Sall has been appointed as Executive Director of Manufacturing and Supply Chain at CEPI.
- Ana Clara C. has joined CEPI as Executive Assistant to Executive Director EIR in Norway, previously holding a position at another company.
- CEPI is hiring an Executive Assistant to the Deputy CEO in London with applications closing on January 15, 2025.
- CEPI is hiring for roles focused on innovative technologies to rapidly respond to disease outbreaks, with applications due by February 9.
🤖 CEPI Developer, Integration and Automation News
- CEPI and the Gates Foundation launched GS-LEARN to provide rapid epidemic modeling for future infectious disease threats by January 15, 2025.
- CEPI and the U.S. International Development Finance Corporation announced a collaboration to enhance global health security by investing in vaccine initiatives and exploring pandemic financing tools.
- CEPI signed strategic agreements with Bio-Manguinhos to expand technological capabilities focusing on RNA and viral vector platforms.
- CEPI's CEO, Dr. Richard Hatchett, announced a new collaboration to enhance regional health security and ensure affordable doses for local populations.
- CEPI announced a partnership with Aspen Pharma to produce vaccines in Africa.
- CEPI has partnered with Accumulus Synergy to enhance information equity and accelerate vaccine access by supporting a regulatory collaboration platform with $19.1 million in funding.
- CEPI has been supplied with antibody testing kits by Zalgen, which also provides diagnostics and reagents to CEPI-funded vaccine developers.
📈 CEPI Financials, Fundraising and Valuation News
- CEPI is funding a $6.4 million project to help Vaxxas develop a needle-free vaccination platform for mRNA vaccines.
- CEPI provided funding to Christian Drosten, a researcher at Charité, along with other organizations like WHO and the Bill and Melinda Gates Foundation.
- CEPI is funding a $9.9 million vaccine safety project in Africa led by the Global Vaccine Data Network to study adverse events in African populations.
- CEPI has funded Abera Bioscience for the development of mucosal vaccines.
- CEPI is funding the development of rapid response platforms and mRNA vaccines for 'Disease X' and has invested in Jurata Thin Film Inc. to produce needle-free vaccine wafers.
- CEPI has committed up to $101 million to support advanced development of three chikungunya vaccine candidates, including Valneva's, which is the first to receive approval from a strict regulatory authority.
- CEPI is funding up to $10.3 million for the ACHIEVE study on chikungunya over three years.
- CEPI is providing up to USD 40 million in initial funding to support SK bioscience's joint R&D project for mRNA vaccine development.
People also viewed
- Amber Beverage Group |
- INVL Asset Management |
- General Atlantic |
- Galinta |
- Groglass |
- Rimi Baltic Group |
- FERN Group |
- HansaMatrix
